Celularity Inc. is a regenerative and cellular medicine company. The Company is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. It develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Biovance 3L, CentaFlex, Interfyl and Rebound products.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 16.60% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 26.55M.
Overvalued
The company’s latest PE is -0.17, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 3.75M shares, decreasing 6.45% quarter-over-quarter.